Because Truveta data provides timely, complete electronic health record data including prescriptions and medication dispense data that captures a large and diverse patient population, weve been able to compare the head-to-head effectiveness of these two important medications for weight loss in advance of smaller randomized clinical trials, Patricia J

Lead author, Luis-Emilio Garca-Prez, MD, PhD, MBA, explained the key findings to Medical News Today : This was a post-hoc sub-group data analysis of the SURMOUNT-1, SURMOUNT-2, SURMOUNT-3 and SURMOUNT-4 phase 3 trials that showed tirzepatide injections (5 mg, 10 mg, 15 mg) significantly reduced body weight compared to placebo regardless of sex, with greater body weight reduction associated with tirzepatide in females compared to males. Luis-Emilio Garca-Prez, MD While the SM-1 and SM-2 trials involved randomization immediately after a screening period, SM-3 had a 12-week lead-in phase with intensive lifestyle changes, and SM-4 had a 36-week lead-in with open-label tripeptide treatment
CJC-1295 increases the number of somatotroph cells actively synthesizing growth hormone, effectively increasing the pool of available hormone
Click here for complete eligibility criteria and approval process
Common Areas Affected After GLP-1 Weight Loss After major weight reduction, certain areas tend to show the most visible changes